New Perspectives on Polycythemia Vera: From Diagnosis to Therapy.

Iurlo A, Cattaneo D, Bucelli C, Baldini L.Int J Mol Sci. 2020 Aug 13;21(16):5805. doi: 10.3390/ijms21165805

Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy).

Fattizzo B, Giannotta JA, Barcellini W, Barbanti MC, Bucelli C, Cassin R, Cattaneo D, Cavallaro F, Ferla V, Fracchiolla NS, Freyrie A, Galassi G, Goldaniga MC, Grifoni FI, Iurlo A, Mangiameli G, Mattiello V, Meli M, Neri A, Noto A, Onida F, Ottani L, Pasquale R, Pettine L, Pompa A, Reda G, Rossi FG, Saporiti GN, Sciumè M, Tagliaferri E, Baldini L.Blood Adv. 2020 Jul 14;4(13):2996-2999. doi: 10.1182/bloodadvances.2020002120

Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality.

Fattizzo B, Giannotta JA, Sciumè M, Cattaneo D, Bucelli C, Fracchiolla NS, Onida F, Baldini L, Barcellini W, Iurlo A.Leukemia. 2020 Jul;34(7):1957-1960. doi: 10.1038/s41375-020-0877-y. Epub 2020 May 26

The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects.

Fattizzo B, Rosa J, Giannotta JA, Baldini L, Fracchiolla NS.Front Oncol. 2020 Feb 28;10:273. doi: 10.3389/fonc.2020.00273. eCollection 2020

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.

Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B.J Clin Med. 2020 Nov 27;9(12):3859. doi: 10.3390/jcm9123859

Difficult Cases of Autoimmune Hemolytic Anemia: A Challenge for the Internal Medicine Specialist.

Fattizzo B, Giannotta JA, Serpenti F, Barcellini W.J Clin Med. 2020 Nov 27;9(12):3858. doi: 10.3390/jcm912385

Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The “Seed and Soil” Crosstalk.

Fattizzo B, Giannotta JA, Barcellini W.Int J Mol Sci. 2020 Jul 30;21(15):5438. doi: 10.3390/ijms21155438

The Changing Landscape of Autoimmune Hemolytic Anemia.

Barcellini W, Fattizzo B.Front Immunol. 2020 Jun 3;11:946. doi: 10.3389/fimmu.2020.00946. eCollection 2020

Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients.

Fattizzo B, Giannotta J, Zaninoni A, Kulasekararaj A, Cro L, Barcellini W.Front Immunol. 2020 Jun 4;11:1006. doi: 10.3389/fimmu.2020.01006. eCollection 2020

Cold agglutinin disease revisited: a multinational, observational study of 232 patients.

Berentsen S, Barcellini W, D’Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE.Blood. 2020 Jul 23;136(4):480-488. doi: 10.1182/blood.2020005674

Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures.

Barcellini W, Giannotta J, Fattizzo B.Expert Rev Hematol. 2020 Jun;13(6):585-597. doi: 10.1080/17474086.2020.1754791. Epub 2020 Apr 29

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects.

Fattizzo B, Barcellini W.Front Oncol. 2020 Jan 10;9:1435. doi: 10.3389/fonc.2019.01435. eCollection 2019

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.

Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J, Riches JC, Zwicker J, Patell R, Vekemans MC, Scarfò L, Chatzikonstantinou T, Yildiz H, Lattenist R, Mantzaris I, Wood WA, Hicks LK.Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824

Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria.

Fattizzo B, Kulasekararaj AG.BioDrugs. 2020 Apr;34(2):149-158. doi: 10.1007/s40259-019-00401-1

Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.

Iurlo A, Cattaneo D, Malato A, Accurso V, Annunziata M, Gozzini A, Scortechini AR, Bucelli C, Scalzulli E, Attolico I, Maggi A, Martino B, Caocci G, Abruzzese E, Pregno P, Luciano L, Breccia M.Am J Hematol. 2020 Oct;95(10):E260-E263. doi: 10.1002/ajh.25908. Epub 2020 Jul 7

Management of Myelofibrosis: from Diagnosis to New Target Therapies.

Iurlo A, Cattaneo D, Bucelli C.Curr Treat Options Oncol. 2020 Apr 30;21(6):46. doi: 10.1007/s11864-020-00734-y

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.

Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Carpenedo M, Randi ML, Bertozzi I, Paoli C, Specchia G, Ricco A, Vannucchi AM, Rodeghiero F, Patrono C, De Stefano V.Blood. 2020 Jul 9;136(2):171-182. doi: 10.1182/blood.2019004596

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

Dragani M, Rege Cambrin G, Berchialla P, Dogliotti I, Rosti G, Castagnetti F, Capodanno I, Martino B, Cerrano M, Ferrero D, Gambacorti-Passerini C, Crugnola M, Elena C, Breccia M, Iurlo A, Cattaneo D, Galimberti S, Gozzini A, Bocchia M, Lunghi F, Cedrone M, Sgherza N, Luciano L, Russo S, Santoro M, Giai V, Caocci G, Levato L, Abruzzese E, Sora F, Saglio G, Fava C.J Clin Med. 2020 Nov 17;9(11):3692. doi: 10.3390/jcm911369

Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.

Mulas O, Caocci G, Annunziata M, Martino B, Luciano L, Castagnetti F, Pregno P, Galimberti S, Albano F, Orlandi EM, Sgherza N, Iurlo A, Bonifacio M, Binotto G, Gozzini A, Bocchia M, Abruzzese E, Fozza C, Simula MP, De Gregorio F, Gugliotta G, Pirillo F, Baratè C, Attolico I, Elena C, Cattaneo D, Scaffidi L, Sicuranza A, Trawinska MM, Scalzulli E, Foà R, Breccia M, La Nasa G.Hematol Oncol. 2020 Oct;38(4):607-610. doi: 10.1002/hon.2765. Epub 2020 Jul 23

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.

Caocci G, Mulas O, Capodanno I, Abruzzese E, Iurlo A, Luciano L, Albano F, Annunziata M, Tiribelli M, Bonifacio M, Galimberti S, Castagnetti F, Sgherza N, Stagno F, Gozzini A, Orlandi EM, Luzi D, Binotto G, Pregno P, Fozza C, Efficace F, Simula MP, Trawinska MM, Cattaneo D, De Gregorio F, Attolico I, Stella R, Scaffidi L, Baratè C, Gugliotta G, Scalzulli E, Elena C, Pirillo F, Foà R, Breccia M, Nasa G.Blood Cancer J. 2020 Jun 8;10(6):66. doi: 10.1038/s41408-020-0333-2

Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.

Mulas O, Caocci G, Stagno F, Bonifacio M, Annunziata M, Luciano L, Orlandi EM, Abruzzese E, Sgherza N, Martino B, Albano F, Galimberti S, Pregno P, Bocchia M, Castagnetti F, Tiribelli M, Binotto G, Gozzini A, Capodanno I, Fozza C, Luzi D, Efficace F, Simula MP, Scaffidi L, De Gregorio F, Elena C, Trawinska MM, Cattaneo D, Attolico I, Baratè C, Pirillo F, Sicuranza A, Gugliotta G, Stella R, Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G.Ann Hematol. 2020 Jul;99(7):1525-1530. doi: 10.1007/s00277-020-04102-6. Epub 2020 May 30

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.

Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, Martino B, Abruzzese E, Bergamaschi M, Heidel FH, Cavazzini F, Crugnola M, Bosi C, Isidori A, Auteri G, Forte D, Latagliata R, Griguolo D, Cattaneo D, Trawinska M, Bartoletti D, Krampera M, Semenzato G, Lemoli RM, Cuneo A, Di Raimondo F, Vianelli N, Cavo M, Palumbo GA.Hematol Oncol. 2020 Aug;38(3):372-380. doi: 10.1002/hon.2737. Epub 2020 Apr 20

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.

De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.Blood. 2020 Jan 30;135(5):381-386. doi: 10.1182/blood.2019002614

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.

Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N.Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20

Second cancers in MPN: Survival analysis from an international study.

Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.Am J Hematol. 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700. Epub 2019 Dec 22

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.

Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M, Orlandi EM, Albano F, Galimberti S, Iurlo A, Pregno P, Sgherza N, Martino B, Binotto G, Castagnetti F, Gozzini A, Bocchia M, Fozza C, Stagno F, Simula MP, De Gregorio F, Trawinska MM, Scaffidi L, Elena C, Attolico I, Baratè C, Cattaneo D, Pirillo F, Gugliotta G, Sicuranza A, Molica M, La Nasa G, Foà R, Breccia M.Int J Cardiol. 2020 Feb 15;301:163-166. doi: 10.1016/j.ijcard.2019.10.036. Epub 2019 Oct 24

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.

Di Buduo CA, Abbonante V, Marty C, Moccia F, Rumi E, Pietra D, Soprano PM, Lim D, Cattaneo D, Iurlo A, Gianelli U, Barosi G, Rosti V, Plo I, Cazzola M, Balduini A.Blood. 2020 Jan 9;135(2):133-144. doi: 10.1182/blood.2019001103

Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, Lunghi F, Scandura JM, Ponzoni M, Hasserjian RP, Gianelli U, Iurlo A, Orazi A.Haematologica. 2020 May;105(5):e221-e224. doi: 10.3324/haematol.2019.230193. Epub 2019 Sep 19

Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL).

Reda G, Noto A, Cassin R, Zamprogna G, Borella C, Scarfò L, Farina L, Molteni A, Ghia P, Tedeschi A, Montillo M; Rete Ematologica Lombarda (REL) Clinical Network.Leukemia. 2020 Sep;34(9):2531-2532. doi: 10.1038/s41375-020-0966-y. Epub 2020 Aug 4

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.

Gemelli M, Elli EM, Elena C, Iurlo A, Intermesoli T, Maffioli M, Pungolino E, Carraro MC, D’Adda M, Lunghi F, Anghileri M, Polverelli N, Rossi M, Bacciocchi M, Bono E, Bucelli C, Passamonti F, Antolini L, Gambacorti-Passerini C.Blood Res. 2020 Sep 30;55(3):139-145. doi: 10.5045/br.2020.2020130